Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study

Irish Journal of Medical Science

Volumn 184, Issue 4, 2015, Pages 753-759

  Li, F ^a   Guo, Z ^a   Zhang, Y ^a   Wang, H ^a   Zhang, X ^b   Si, T ^a   Yu, H ^a   Qi, L ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Texas Cancer Center   (United States)

Author keywords

HBV related; Hepatocellular carcinoma; Regulatory T cells; Surgery; Transcatheter arterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; EPIRUBICIN; HEPATITIS B(E) ANTIGEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SEROLOGY; STOMACH DISCOMFORT; TREATMENT RESPONSE; WEDGE RESECTION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ADULT; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84945496693     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-014-1164-6     Document Type: Article

References (36)

1. Rilling WS, Drooz A (2002) Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol 13:S259–S263
2. Lencioni R, Chen XP, Dagher L et al (2010) Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15:42–52
3. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044
4. Lai MY, Chen DS, Chen PJ et al (1998) Status of hepatitis B virus DNA in hepatocellular carcinoma: a study based on paired tumor and nontumor liver tissues. J Med Virol 25:249–258
5. Kim BK, Park JY, Kim do Y et al (2008) Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 28:393–401
6. Chuma M, Hige S, Kamiyama T et al (2009) The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 44:991–999
7. Yang T, Lu JH, Zhai J et al (2012) High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol 38:683–691
8. Kubo S, Hirohashi K, Tanaka H et al (2001) Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg 18:26–33
9. Ohkubo K, Kato Y, Ichikawa T et al (2002) Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 94:2663–2668
10. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524
11. El-Serag HB, Marrero JA, Rudolph L et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763
12. Hanazaki K, Kajikawa S, Shimozawa N et al (2002) Hepatic resection for hepatocellular carcinoma in diameter of ≥10 cm. Hepatogastroenterology 49:518–523
13. Ng KK, Vauthey JN, Pawlik TM et al (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364–373
14. Lin CT, Hsu KF, Chen TW et al (2010) Comparing hepatic resection and transarterial chemoembolization for barcelona clinic liver cancer (BCLC) Stage B hepatocellular carcinoma: change for treatment of choice? World J Surg 34:2155–2161
15. Tsai TJ, Chau GY, Lui WY et al (2000) Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 127:603–608
16. Zhu AX (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11:790–800
17. Yeo W, Mok TS, Zee B et al (2005) A randomized phase III study of Doxorubicin versus cisplatin/interferon alpha-2b/Doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532–1538
18. Leung TW, Patt YZ, Lau WY et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681
19. Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33:S134–S138
20. Okada S (1998) Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 27:1743–1744
21. Mathurin P, Raynard B, Dharancy S et al (2003) Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 17:1247–1261
22. Tanaka K, Shimada H, Togo S et al (1999) Use of transcatheter arterial infusion of anti-cancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 46:1083–1088
23. Fukuda S, Okuda K, Imamura M et al (2002) Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 131:300–310
24. Xi T, Lai EC, Min AR et al (2012) Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology 59:1198–1203
25. Pringle JH (1908) Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg 48:541–549
26. Liao KF, Lai SW, Lin CY et al (2011) Risk factors of recurrence after curative resection of hepatocellular carcinoma in Taiwan. Am J Med Sci 341:301–304
27. Chang SKY, Hlaing WW, Yu RQ et al (2012) Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection. Singap Med J 53:32–35
28. Lai CL, Ratziu V, Yuen MF et al (2003) Viral hepatitis B. Lancet 362:2089–2094
29. Chen CH, Huang GT, Yang PM et al (2006) Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 42:2524–2529
30. Shijo H, Okazaki M, Koganemaru F et al (1991) Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma. Cancer 67:2626–2632
31. Lai EC, Lo CM, Fan ST et al (1998) Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133:183–188
32. Chen L, Zhang Q, Chang W et al (2012) Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 48:1977–1987
33. Chen JD, Yang HI, Iloeje UH et al (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747–1754
34. Ren ZG, Lin ZY, Xia JL et al (2004) Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 10:2791–2794
35. Zhong C, Guo RP, Li JQ et al (2009) A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III a hepatocellular carcinoma. J Cancer Res Clin Oncol 135:1437–1445
36. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628–636